Launched in late 2021, GEOMETRY-E, a randomized, controlled, open-label, multicenter, phase 3 study was designed to evaluate the efficacy and safety of capmatinib plus osimertinib and compare it to the current standard of care treatment of platinum pemetrexed doublet chemotherapy in patients with advanced or metastatic EGFR-mutated, T790M-negative NSCLC with MET amplification, who had progressed on either first-, second-, or third-generation EGFR TKI. Here, EGFR is linked to non-small cell lung carcinoma.